View this webinar to learn product characterization strategies to de-risk manufacturing and detect and characterize host cell proteins and polyethylenimine (PEI) in monoclonal antibody (mAb) and cell and gene therapies.
The intrinsic complexity of developing and manufacturing antibody-drug conjugates (ADCs) creates major challenges when trying to bring life-saving therapies to market. Combating the challenges of developing and manufacturing ADCs requires robust product characterization throughout all phases of development.
Because characterization and comparison of originator and biosimilar candidate monoclonal antibodies (mAbs) is challenging due to their complex and variable structures, a range of analytical techniques should be employed.
In this webinar, multiple approaches to characterizing the physicochemical and structural attributes of therapeutic monoclonal antibodies (mAbs) is presented with a focus on how it influences the resulting biological activity.